APDN adnas.com Accounting Capitalization

Public company logo of adnas.com (APDN)

Applied DNA Sciences (APDN) creates unique product protection tools, leveraging its patent portfolio and close ties to the defense sector. A portion of the verification processes and IT infrastructure has been outsourced to external partners, with the indicator standing at 0.01. Stable cash flow from laboratory operations covers investments, which is reflected in the pakistan asset value chart presented below for this company.

adnas.com (APDN) - Company Book Value from 07/04/2022 to 10/07/2025

Applied DNA Sciences, Inc. - analytical breakdowns and key metrics (APDN)

- price and consensus price forecast:
Share Price Applied DNA Corp|APDN - Price Target Chart
- market capitalization data:
Market Capitalization Applied DNA Sciences Inc|APDN - Enterprise Value
- book capitalization data:
Equity per Share Applied DNA Sciences|APDN - Company Book Value|Capitalization to Book Value Ratio adnas.com|APDN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Applied DNA Sciences|APDN - Long-Term Debt to Capital|Short-Term Debt to Capital Applied DNA Sciences Inc|APDN - Company Debts|Debts to Book Capitalization Ratio Applied DNA Sciences Inc
Comprehensive company analysis:Applied DNA Corp - APDN
Mass-produced product of Applied DNA Sciences, Inc.

For the high-tech Applied DNA Sciences (APDN), whose value is based on unique patents and personnel, the company's book value serves as a filter for asset stability. This metric reflects net assets minus liabilities, allowing investors to use this chart to determine the actual backing of each share and separate speculative noise from the fundamental value of the business's scientific and production potential.

Analysis of competing companies

TEM: Accounting Capitalization|Company Book Value Qiagen N.V.|ionispharma.com (IONS) - Accounting Capitalization|Book Capitalization Repligen (RGEN)|Accounting Capitalization RNA|Company Book Value CRISPR Therapeutics Corp CRSP|Accounting Capitalization GeneDx Corp (WGS)|Book Capitalization RARE (Ultragenyx Pharmaceutical)|Book Capitalization beamtx.com BEAM|Sarepta - Book Capitalization|TWST: Book Capitalization|Company Book Value 10x Genomics Corp (TXG)|NTLA (Intellia Corp) - Net Asset Value|Company Book Value Stoke Therapeutics STOK|Net Asset Value BLFS|Company Book Value Wave Life Sciences Ltd. (WVE)|Company Book Value Maze Therapeutics, Inc. (MAZE)|Book Capitalization SION|Book Valuation of Business Prime Medicine Bio PRME|TSHA (Taysha Gene Therapies) - Book Capitalization|QURE - Total Stockholders' Equity|Book Capitalization MeiraGTx|Accounting Capitalization REGENXBIO Inc|SLDB - Company Net Assets|Accounting Value of Company Ocugen Pharma|Book Capitalization Pacific Biosciences PACB|Accounting Capitalization BNTC (benitec.com)|DSGN - Company Book Value|Accounting Capitalization Rocket Pharma RCKT|4D Molecular Therapeutics Inc - Book Capitalization|Lexeo Therapeutics (LXEO) - Book Capitalization|Company Net Assets korrobio.com KRRO|EDIT (editasmedicine.com) - Accounting Value of Company|SLN: Company Book Value|Book Valuation of Business ProQR Therapeutics NV|Book Capitalization CDXS (Codexis, Inc.)|Company Net Assets Sangamo BioSciences (SGMO)|Book Capitalization NAUT|Book Valuation of Business metagenomi.co MGX|DTIL (Precision BioSciences) - Book Capitalization|GBIO: Total Stockholders' Equity|Company Book Value Boundless Bio, Inc|Exicure (XCUR) - Accounting Capitalization|Book Capitalization IMNN|Company Net Assets RXi Pharmaceuticals|Mustang Bio, Inc. - Book Capitalization|Total Stockholders' Equity RNAZ (transcodetherapeutics.com)|Company Book Value BNGO|Book Valuation of Business bluebird bio, Inc BLUE|ImmunoPrecise - Book Capitalization|OMGA: Book Capitalization|Company Book Value Singular Genomics (OMIC)|Regulus Therapeutics, Inc. (RGLS) - Net Asset Value|Book Capitalization Syros (SYRS)|Accounting Capitalization TBIO|Company Book Value TRACON Pharmaceuticals TCON|Accounting Capitalization unitybiotechnology.com (UBX)